论文部分内容阅读
[目的]评价脂质体紫杉醇(力扑素)联合顺铂、氟尿嘧啶(5-Fu)组成的PCF方案一线治疗43例晚期胃癌的临床疗效和毒副反应。[方法]脂质体紫杉醇135～175mg/m2,静滴3h,d1;顺铂20mg/m2,静滴2h,d1～5;5-Fu750mg/m2持续静脉滴注d1～5。21d为1个周期。按RECIST标准评定疗效,按WHO标准评价毒副反应,Kaplan-Meier法绘制生存曲线。[结果]全组共完成化疗167个周期,中位治疗3个周期。39例患者完成2个周期以上化疗并可评价疗效,其中CR1例,PR19例,SD11例,PD8例,总有效率51.3%。中位无进展生存时间6.0个月,中位总生存时间11.5个月,1年生存率41.0%。主要的Ⅲ~Ⅳ级血液学毒性为白细胞减少及中性粒细胞减少,发生率分别为16.2%和25.6%。全组仅1例发生过敏反应。无患者因毒性反应而停药,无治疗相关性死亡发生。[结论]脂质体紫杉醇联合顺铂及氟尿嘧啶一线治疗晚期胃癌疗效肯定,毒副反应轻,对患者生活质量改善明显。
[Objective] To evaluate the clinical efficacy and side effects of first-line PCF regimen consisting of liposomal paclitaxel combined with cisplatin and 5-fluorouracil in the treatment of 43 advanced gastric cancer patients. [Method] Liposomal paclitaxel 135-175mg / m2, intravenous drip 3h, d1; cisplatin 20mg / m2, intravenous drip 2h, d1-5; 5-Fu750mg / m2 continuous d1 ~ 5.21d as a cycle. According to RECIST standard assessment of efficacy, according to WHO standard evaluation of toxic reactions, Kaplan-Meier method survival curve. [Results] All patients completed 167 cycles of chemotherapy and 3 cycles of median treatment. 39 patients completed more than two cycles of chemotherapy and can evaluate the efficacy, including CR1 cases, PR19 cases, SD11 cases, PD8 cases, the total efficiency of 51.3%. The median progression-free survival time was 6.0 months, the median overall survival time was 11.5 months and the 1-year survival rate was 41.0%. The major grade Ⅲ ~ Ⅳ hematologic toxicities were leukopenia and neutropenia, with rates of 16.2% and 25.6%, respectively. The whole group only 1 case of allergic reactions. No patients discontinued due to toxicity and no treatment-related deaths occurred. [Conclusion] The efficacy of liposomal paclitaxel combined with cisplatin and fluorouracil in the first-line treatment of advanced gastric cancer is affirmative, and the side effects are mild and the patients’ quality of life is improved obviously.